What were Yutrepia's sales in Q1 2026?

Yutrepia generated $130 million in sales in Q1 2026.

Did LQDA achieve profitability from Yutrepia?

Yes, LQDA's profitability improved due to rising Yutrepia sales and prescriptions.

What competition does Yutrepia face?

Yutrepia competes with drugs like Tyvaso and Orenitram in the PAH market.

What is Yutrepia's impact on LQDA stock?

Yutrepia is expected to significantly contribute to LQDA's 2026 revenue, boosting investor confidence.

Yutrepia Launch Drives LQDA's Q1 2026 Sales Surge

LQDA reported strong Yutrepia sales of $130 million in Q1 2026, with increasing prescriptions and improved profitability as the company expands in the pulmonary arterial hypertension (PAH) market.

July 2, 2026

2 min read

Source: Zacks

Key Numbers

q1 sales

130M

quarter

Q1 2026

LQDA's Yutrepia launch is gaining traction, with $130 million in Q1 sales, rising prescriptions and profitability as the company expands in PAH.

The Product

Yutrepia is a treatment for pulmonary arterial hypertension (PAH), a serious condition affecting lung arteries, causing shortness of breath and fatigue. Its innovative mechanism offers an option for patients unresponsive to traditional therapies.

Pricing and Availability

LQDA has not disclosed specific pricing details, but Yutrepia is expected to be available in key markets through specialized prescriptions. The company is expanding distribution to more medical centers.

Competition

Yutrepia faces competition from other PAH drugs such as Tyvaso and Orenitram. However, its unique formulation and growing prescription numbers suggest it can capture increasing market share.

Potential Impact on the Company

With Yutrepia's momentum continuing, the drug is expected to contribute significantly to LQDA's 2026 revenue. Improved profitability also boosts confidence in the company's sustainable growth.

Frequently Asked Questions

Yutrepia is a drug used to treat pulmonary arterial hypertension (PAH), a condition affecting lung arteries that causes breathing difficulty.

Found this useful? Share it

This article was rewritten in Wrqti's editorial style based on information from the original source above. Content is informational only — not investment advice.